{
    "root": "2fc526c9-107e-a378-e063-6294a90a2b54",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valacyclovir Hydrochloride",
    "value": "20250307",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE K90",
            "code": "RDH86HJV5Z"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "VALACYCLOVIR HYDROCHLORIDE",
            "code": "G447S0T1VC"
        }
    ],
    "indications": "Valacyclovir hydrochloride is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients (1.1) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1-infected patients Reduction of transmission Herpes Zoster Pediatric Patients (1.2) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use (1.3) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients.",
    "contraindications": "Valacyclovir tablets may be given without regard to meals.\n                     \n                        Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from 500 mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate\n   \n    [see\n    \n     Dosage and Administration (2.3)]\n   \n    .",
    "warningsAndPrecautions": "Valacyclovir Tablets USP, 500 mg are blue, film-coated, capsule shaped tablets with “F 82” on one side and plain on the otherside containing 556 mg of valacyclovir hydrochloride equivalent to 500 mg of valacyclovir.\n                  NDC: 70518-2266-00\n                  NDC: 70518-2266-01\n                  NDC: 70518-2266-02\n                  NDC: 70518-2266-03\n                  NDC: 70518-2266-04\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 6 in 1 BOTTLE PLASTIC\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20o to 25oC (68o to 77oF). [See USP Controlled Room Temperature.]\n                  Dispense in a well-closed container as defined in the USP.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation\n \n  [see\n  \n   Adverse Reactions (6.3)]\n \n  ."
}